Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended October 31, 2003
Business Overview: Cooper develops, manufactures, and markets healthcare products through two principal segments: CooperVision (CVI), specializing in contact lenses (toric, cosmetic, and specialty lenses), and CooperSurgical (CSI), providing medical devices and surgical instruments for gynecologists and obstetricians. As of October 31, 2003, the Company employed approximately 3,700 people.
Key Financial Metrics
Debt and Liquidity:
Total debt increased to $185.9 million at October 31, 2003, from $163.6 million at October 31, 2002. This increase was driven by the issuance of $115 million in convertible senior debentures, proceeds of which were used to reduce amounts drawn under the revolving credit facility and for additional funding requirements.
| Debt Category | Oct 31, 2003 ($ millions) | Oct 31, 2002 ($ millions) |
|---|---|---|
| Short-term debt | $20.7 | $36.3 |
| Long-term debt | $165.2 | $127.3 |
| Total Debt | $185.9 | $163.6 |
Research and Development (R&D):
Company-sponsored R&D expenditures were $5.6 million for fiscal 2003, compared to $4.3 million in 2002 and $3.7 million in 2001. CooperVision accounted for 68% of total R&D spending in 2003.
Revenue, Profit, and Cash Flow:
The filing text does not provide specific values for total revenue, net income, operating margins, or cash flow. These figures are incorporated by reference to the 2003 Annual Report to Stockholders.
Material Changes and Operational Highlights
- Debt Structure: Significant shift in capital structure with the issuance of $115 million in convertible senior debentures in fiscal 2003.
- R&D Investment: Continued increase in R&D spending, rising 30% from the prior year ($4.3M to $5.6M), reflecting ongoing product development efforts.
- Market Position: CVI competes in a $3.5 billion global contact lens market, with approximately 62% of its sales derived from the specialty segment (toric, cosmetic, multifocal). CVI holds approximately 30% of the global toric lens market.
- Regulatory Compliance: The Company maintains ISO 9000 certification and CE mark approvals. All currently marketed products have been cleared by appropriate regulatory agencies.
Guidance, Risks, and Management Commentary
Forward-Looking Statements: The Company cautions that statements regarding anticipated growth, market conditions, and results of operations are forward-looking and subject to risks. These include major changes in business conditions, manufacturing disruptions, new competitors, regulatory issues (including product recalls), and the impact of healthcare reform legislation.
Market Risks:
The Company is exposed to interest rate changes and foreign currency fluctuations. It utilizes interest rate swaps and foreign currency forward exchange contracts to minimize exposure but does not engage in speculative derivative transactions.
Seasonality:
CVI sales are typically lower in the first fiscal quarter (November through January) due to reduced patient traffic during the holiday season.
Legal Proceedings:
The Company reported no material legal proceedings as of the filing date.
Investor Verification Checklist
- Financial Performance: Verify total revenue, net income, and cash flow figures in the incorporated 2003 Annual Report to Stockholders, as they are not explicitly stated in this 10-K text.
- Debt Covenants: Review the terms of the $115 million convertible senior debentures and the impact on future interest obligations and potential dilution.
- Regulatory Status: Confirm the status of any pending FDA approvals for new products, as delays could materially impact future revenue.
- Competitive Landscape: Assess the impact of major competitors (Johnson & Johnson, Novartis, Bausch & Lomb) on market share, particularly in the specialty contact lens segment.
- Acquisition Integration: Evaluate the integration progress and financial contribution of the Biocompatibles Eye Care acquisition (completed in 2002) to the Proclear product line.